In 2023, Brazil was by far the Latin American country with the highest pharmaceutical market value, amounting to around 37.3 billion U.S. dollars. Mexico ranked second, with a pharma market value of approximately 12.9 billion U.S. dollars. As a whole, Latin America accounted for about 4.2 percent of the global 2023 pharmaceutical market revenue. An industry driven by importsBrazil produced more than 52 billion Brazilian reals worth of pharmaceutical products in 2020. Despite its significant role in the national economy, the pharmaceutical industry in this South American country relies mostly on imports. In 2021, Brazil had pharmaceutical imports for about 11 billion U.S. dollars in 2021. Meanwhile, Brazil’s pharma exports have declined from 1.57 billion U.S. dollars in 2014 to 1.24 billion U.S. dollars in 2023. ACHE Laboratorios – a national market leaderDespite U.S companies such as Pfizer leading the global pharmaceutical industry, in Brazil Aché Laboratorios Farmacéuticos S.A. - a prominent 100-percent Brazilian pharmaceutical corporation – ranks first in the segment, with a revenue of over four billion Brazilian reals in 2021. Focusing mostly on the production and sales of prescription drugs, the company invested more than 81.5 billion reals in research, development, and innovation in 2018.
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
Latin America's Biologics Drug Development market will be USD 377.56 million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031. The market is foreseen to reach USD 708.4 million by 2031 due to increasing prevalence of chronic diseases.
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
Latin America's Pharmaceutical CXO market will be USD XX million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031. The market is foreseen to reach USD XX million by 2031 due to its attractive destination for clinical trials due to its diverse patient population, which offers a broad spectrum of genetic backgrounds and health conditions.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 1589.81(USD Billion) |
MARKET SIZE 2024 | 1671.85(USD Billion) |
MARKET SIZE 2032 | 2500.0(USD Billion) |
SEGMENTS COVERED | Product Type ,Therapeutic Area ,Route of Administration ,Dosage Form ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising demand for personalized medicine Technological advancements in drug discovery and manufacturing Increasing prevalence of chronic diseases Globalization of clinical trials Focus on costeffective and efficient drug manufacturing |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Johnson & Johnson ,Eli Lilly and Company ,Takeda Pharmaceutical Company ,GlaxoSmithKline ,Bayer ,Novartis ,Teva Pharmaceutical Industries ,AbbVie ,Sanofi ,Roche ,Merck & Co. ,Bristol Myers Squibb ,AstraZeneca ,Pfizer ,Daiichi Sankyo |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Biosimilar Development Targeted Therapies Drug Repurposing Personalized Medicine Digital Health Integration |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.16% (2025 - 2032) |
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 6.88(USD Billion) |
MARKET SIZE 2024 | 7.42(USD Billion) |
MARKET SIZE 2032 | 13.5(USD Billion) |
SEGMENTS COVERED | Service Type, Therapeutic Area, Client Type, Product Type, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising demand for biologics, Increasing R&D investment, Growing regulatory complexity, Expansion of outsourcing services, Technological advancements in manufacturing |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | WuXi AppTec, Merck KGaA, Lonza, Novartis, Catalent, Recipharm, PPD, Baxter, Snyder Pharmaceuticals, Aenova, Evonik Industries, Resilience, Boehringer Ingelheim, Samsung Biologics, Famar |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Increasing demand for personalized medicine, Growth of biologics and biosimilars, Expansion of outsourcing trends, Advancements in biomanufacturing technologies, Rise in healthcare expenditure globally |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.78% (2025 - 2032) |
https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
Market Size and Drivers: The Latin America pharmaceutical plastic packaging market was valued at USD 3.51 billion in 2025 and is projected to reach USD 6.28 billion by 2033, exhibiting a CAGR of 6.79%. This growth is primarily driven by the rising demand for pharmaceuticals and healthcare products, advancements in drug delivery systems, and increasing consumer preference for convenient and safe packaging solutions. Additionally, the growing healthcare infrastructure and population in Latin America further augment the market's expansion. Key Trends and Restraints: Notable trends shaping the market include the adoption of sustainable materials like biodegradable and recyclable plastics, the integration of advanced technologies such as RFID and QR codes for product traceability, and the increasing use of unit-dose packaging. However, challenges like fluctuating raw material prices, competition from alternative packaging materials, and regulatory compliance issues may hinder market growth to some extent. The analysis also segments the market by raw material, product type, and company, providing valuable insights into the competitive landscape and industry dynamics within the Latin America pharmaceutical plastic packaging market. Recent developments include: June 2024 - BERICAP expands production in Africa, South America and South East Asia, BERICAP recently invested in another plant in Africa and now also has operations in South Africa. Peru is BERICAP’s fourth production site in Latin America and is said to also allow good access to Bolivia, the northern part of Chile and Ecuador, totalling around 60 million consumers. The new 5,000 m² production facility is situated in Lima with 50 employees. The BERICAP team in Peru is supported by the teams at BERICAP do Brazil and BERICAP Argentina., January 2024 – ALPLA has purchased Fortiflex, a packaging specialist located in Puerto Rico, which produces buckets, canisters, crates, barrels, and closures. Both companies have been collaboratively manufacturing packaging for the Caribbean and Central American markets since 2017. By acquiring Fortiflex, ALPLA bolsters the ALPLAindustrial division created in 2023 for big-size packaging solutions and broadens its range as a comprehensive supplier. The ALPLA Group is speeding up the manufacturing of high-capacity plastic containers. The global packaging and recycling expert has purchased full ownership of the packaging firm Fortiflex, Inc., located in Puerto Rico.. Key drivers for this market are: Need for Protective and Barrier-Resistant Packaging for Pharmaceutical Products Propel the Sales of Plastic Bottles and Containers, Rising Aging Population in the Region is Fueling the Demand for Convenient Pharmaceutical Packaging Solutions such as Blisters. Potential restraints include: Need for Protective and Barrier-Resistant Packaging for Pharmaceutical Products Propel the Sales of Plastic Bottles and Containers, Rising Aging Population in the Region is Fueling the Demand for Convenient Pharmaceutical Packaging Solutions such as Blisters. Notable trends are: Need for Protective and Barrier-Resistant Packaging for Pharmaceutical Products is Propelling the Sales of Plastic Bottles and Containers.
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
Latin America's silica for pharmaceutical market will be USD XX million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031. The market is foreseen to reach USD XX million by 2031 due to the development of new materials.
https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy
The Latin American pharmaceutical plastic packaging market, valued at $3.51 billion in 2025, is projected to experience robust growth, driven by factors such as the rising prevalence of chronic diseases, increasing demand for pharmaceuticals, and a growing preference for convenient and safe packaging solutions. The market's Compound Annual Growth Rate (CAGR) of 6.79% from 2025 to 2033 indicates a significant expansion, with the market expected to surpass $6 billion by 2033. Key growth drivers include the increasing adoption of advanced packaging technologies like blister packs and modified atmosphere packaging to enhance product shelf life and prevent contamination. Furthermore, stringent regulatory requirements concerning drug safety and packaging standards are pushing the market towards higher-quality, tamper-evident packaging, contributing to this positive growth trajectory. The market is segmented by raw material (polypropylene, polyethylene terephthalate, etc.) and product type (bottles, vials, syringes, etc.), with solid containers and bottles currently dominating the market share. Brazil, Mexico, and Argentina are expected to be the leading contributors to market growth due to their relatively large pharmaceutical sectors and increasing healthcare spending. However, challenges such as economic instability in certain Latin American countries and fluctuating raw material prices pose potential restraints to market growth. The competitive landscape features both multinational corporations and regional players, creating a dynamic interplay of established brands and local expertise. Amcor, Berry Global, and Gerresheimer are some of the key players, offering a diverse range of packaging solutions. The market is also witnessing increasing adoption of sustainable packaging alternatives, driven by growing environmental concerns and regulatory pressures. Companies are focusing on developing recyclable and biodegradable packaging solutions to cater to the evolving consumer preferences and environmental regulations. This shift towards sustainable packaging, coupled with continuous innovation in materials and design, will further shape the future of the Latin American pharmaceutical plastic packaging market. Recent developments include: June 2024 - BERICAP expands production in Africa, South America and South East Asia, BERICAP recently invested in another plant in Africa and now also has operations in South Africa. Peru is BERICAP’s fourth production site in Latin America and is said to also allow good access to Bolivia, the northern part of Chile and Ecuador, totalling around 60 million consumers. The new 5,000 m² production facility is situated in Lima with 50 employees. The BERICAP team in Peru is supported by the teams at BERICAP do Brazil and BERICAP Argentina., January 2024 – ALPLA has purchased Fortiflex, a packaging specialist located in Puerto Rico, which produces buckets, canisters, crates, barrels, and closures. Both companies have been collaboratively manufacturing packaging for the Caribbean and Central American markets since 2017. By acquiring Fortiflex, ALPLA bolsters the ALPLAindustrial division created in 2023 for big-size packaging solutions and broadens its range as a comprehensive supplier. The ALPLA Group is speeding up the manufacturing of high-capacity plastic containers. The global packaging and recycling expert has purchased full ownership of the packaging firm Fortiflex, Inc., located in Puerto Rico.. Key drivers for this market are: Need for Protective and Barrier-Resistant Packaging for Pharmaceutical Products Propel the Sales of Plastic Bottles and Containers, Rising Aging Population in the Region is Fueling the Demand for Convenient Pharmaceutical Packaging Solutions such as Blisters. Potential restraints include: Need for Protective and Barrier-Resistant Packaging for Pharmaceutical Products Propel the Sales of Plastic Bottles and Containers, Rising Aging Population in the Region is Fueling the Demand for Convenient Pharmaceutical Packaging Solutions such as Blisters. Notable trends are: Need for Protective and Barrier-Resistant Packaging for Pharmaceutical Products is Propelling the Sales of Plastic Bottles and Containers.
https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
The size of the Latin America Melanoma Diagnostics and Therapeutics Market market was valued at USD 4 Million in 2023 and is projected to reach USD 9 Million by 2032, with an expected CAGR of 13.80% during the forecast period. The Latin America melanoma diagnostics and therapeutics market is mainly based on the diagnosis and treatment of melanoma which is a particularly dangerous form of skin malignancy. Early detection measures mostly involve dermoscopy and biopsy among other diagnosis measures used in the detection of melanoma. Therapiess include depends on type of therapy including targeted therapy, immunotherapy as well as chemotherapy to address and treat the condition. Observations made point to the expansion of utilization of higher-end diagnostic products; rising interest in precision medicine; and general uptick in targeted therapies because these are precise and less hazardous compared to traditional treatments. Market is also fast expanding because of increased awareness about skin cancer and better healthcare facilities in Latin American region. Recent developments include: In November 2022, Medison Pharma announced the addition of South and Central America and the Caribbean markets, to its multi-territorial agreement with Immunocore Holdings plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer like melanoma, infection and autoimmune disease., In April 2021, Melanoma Research Alliance announced that it is supporting creative partnerships between researchers, for example, a multi-national team of scientists in Mexico, Brazil, and the United Kingdom focused on unraveling the ways in which acral melanoma spreads throughout the body.. Key drivers for this market are: Increasing Incidences of Melanoma Cases, Advancements in Diagnosis and Treatments and Rising Government Initiatives. Potential restraints include: Lack of Awareness and High Cost Associated With the Therapy. Notable trends are: Biological Therapy is Expected to Witness High Growth Over the Forecast Period.
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global market size of Contract Pharmaceutical is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Contract Pharmaceutical Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Contract Pharmaceutical industry. The key insights of the report:
1.The report provides key statistics on the market status of the Contract Pharmaceutical manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of Contract Pharmaceutical industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of Contract Pharmaceutical Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of Contract Pharmaceutical as well as some small players.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share
For product type segment, this report listed main product type of Contract Pharmaceutical market
* Product Type I
* Product Type II
* Product Type III
For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Application I
* Application II
* Application III
For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 0.35(USD Billion) |
MARKET SIZE 2024 | 0.37(USD Billion) |
MARKET SIZE 2032 | 0.477(USD Billion) |
SEGMENTS COVERED | Application ,End User ,Distribution Channel ,Grade ,Region ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | 1 Rising demand in pharmaceutical industry 2 Growing personal care and cosmetics market 3 Increasing investment in RampD for new applications 4 Fluctuating raw material prices 5 Stringent environmental regulations |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Tosoh Corporation ,SABIC ,Formosa Plastics Corporation ,China Petroleum & Chemical Corporation ,BASF SE ,The Dow Chemical Company ,Indorama Ventures PCL ,LG Chem ,Merck KGaA ,Huntsman Corporation ,Lanxess ,Kuraray Co., Ltd. ,Evonik Industries AG ,Zeon Corporation |
MARKET FORECAST PERIOD | 2024 - 2032 |
KEY MARKET OPPORTUNITIES | 1 Growing demand from pharmaceutical industry 2 Expanding applications in food and beverage 3 Increasing adoption in cosmetics and personal care 4 Emerging markets with high potential 5 Technological advancements driving innovation |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.37% (2024 - 2032) |
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
Latin America's Antibody Conjugates Drug market will be USD 491.26 million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031. The market is foreseen to reach USD 1115.7 million by 2031 due to the need for ADC, which is driven by the aging population, which is increasingly prone to cancer and chronic illnesses.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 39.35(USD Billion) |
MARKET SIZE 2024 | 43.43(USD Billion) |
MARKET SIZE 2032 | 95.55(USD Billion) |
SEGMENTS COVERED | Product Type, Formulation Type, Therapeutic Area, Distribution Channel, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | rising Muslim population demand, regulatory support for halal standards, increasing awareness of halal products, expansion of halal certification bodies, growth in e-commerce distribution channels |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Emergent BioSolutions, Salim Group, Marjan Pharma, Kotra Pharma, Hilal Foods, Nutraceutical Corporation, Haleon, DSM, MediKanvas, Pharmaniaga, Sasa Global, Bahrain Mumtalakat Holding Company, Bajra Pharmaceuticals, Renaissance Health |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Growing Muslim population demand, Rising health consciousness, Expansion in e-commerce platforms, Increasing awareness of halal standards, Development of innovative halal formulations |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.36% (2025 - 2032) |
https://www.archivemarketresearch.com/privacy-policyhttps://www.archivemarketresearch.com/privacy-policy
The global market for Valley Fever (Coccidioidomycosis) medication is experiencing robust growth, driven by increasing incidence rates of the disease, particularly in endemic regions of the southwestern United States, Mexico, and parts of Central and South America. The market, estimated at $1.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching an estimated value of $2.8 billion by 2033. This growth is fueled by several factors, including improved diagnostic capabilities leading to earlier detection and treatment, an expanding elderly population (more susceptible to severe infections), and the emergence of drug-resistant strains necessitating the development of new and more effective antifungal therapies. The market is segmented by application (hospital, retail, others) and medication type (Fluconazole, Voriconazole, Posaconazole, Amphotericin B, others). Fluconazole currently holds a significant market share due to its cost-effectiveness, although the increasing prevalence of resistant strains is driving demand for newer, broader-spectrum azoles like Voriconazole and Posaconazole. Competition is intense among major pharmaceutical companies such as Pfizer, Bayer, Teva Pharmaceuticals, and others, leading to ongoing innovation and the introduction of novel therapies. Geographical variations in market size are significant, with North America accounting for the largest share due to high prevalence and advanced healthcare infrastructure. However, emerging markets in Asia Pacific and South America are expected to demonstrate substantial growth during the forecast period, driven by increasing awareness, improving healthcare access, and rising disposable incomes. Challenges remain, including the relatively low awareness of Valley Fever in non-endemic regions and the need for more effective treatment options for severe or disseminated infections. Ongoing research and development efforts focused on novel antifungal agents and improved diagnostic tools will continue to shape the market's trajectory in the coming years. The market is also influenced by regulatory approvals, pricing pressures, and the overall healthcare landscape.
https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy
Latin America's Gastric Cancer Drug market will be USD 274.21 million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031. The market is foreseen to reach USD 683.8 million by 2031 due to the increasing investment in healthcare infrastructure.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 6.69(USD Billion) |
MARKET SIZE 2024 | 7.16(USD Billion) |
MARKET SIZE 2032 | 12.3(USD Billion) |
SEGMENTS COVERED | Drug Type, Treatment Phase, Patient Age Group, Distribution Channel, Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Growing prevalence of Tourette Syndrome Emerging targeted therapies Rise in government funding for research Technological advancements Expanding reimbursement policies |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | BioMarin Pharmaceutical, Impax Laboratories, US WorldMeds, Neurocrine Biosciences, Eton Pharmaceuticals, Neurelis, Torrent Pharmaceuticals, Novartis AG, Teva Pharmaceutical Industries, AbbVie, Lundbeck, Supernus Pharmaceuticals, Sun Pharmaceutical Industries, Acadia Pharmaceuticals |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Growth of the Central Nervous System CNS Drug Market Increasing Prevalence of Tourette Syndrome Rising Demand for NonPharmacological Therapies Development of Precision Medicine Expanding Pipeline of Novel Drugs |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.01% (2025 - 2032) |
https://www.htfmarketinsights.com/privacy-policyhttps://www.htfmarketinsights.com/privacy-policy
Global Retinal Pharmaceuticals is segmented by Application (Eye Disease Treatment, Retina Disorders, Ophthalmology, Drug Development, Clinical Trials), Type (Pharmaceuticals, Healthcare, Biotechnology, Research, Medical) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)
https://www.htfmarketinsights.com/privacy-policyhttps://www.htfmarketinsights.com/privacy-policy
Global Sexually Transmitted Diseases Drug is segmented by Application (Pharmaceuticals, Research), Type (Pharmaceutical) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)
https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy
The Central Lab Market report segments the industry into By Services (Biomarker Services, Genetic Services, Microbiology Services, Special Chemistry Services, Anatomic Pathology/Histology, Specimen Management & Storage, Other Services), End-User (Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).
In 2023, Brazil was by far the Latin American country with the highest pharmaceutical market value, amounting to around 37.3 billion U.S. dollars. Mexico ranked second, with a pharma market value of approximately 12.9 billion U.S. dollars. As a whole, Latin America accounted for about 4.2 percent of the global 2023 pharmaceutical market revenue. An industry driven by importsBrazil produced more than 52 billion Brazilian reals worth of pharmaceutical products in 2020. Despite its significant role in the national economy, the pharmaceutical industry in this South American country relies mostly on imports. In 2021, Brazil had pharmaceutical imports for about 11 billion U.S. dollars in 2021. Meanwhile, Brazil’s pharma exports have declined from 1.57 billion U.S. dollars in 2014 to 1.24 billion U.S. dollars in 2023. ACHE Laboratorios – a national market leaderDespite U.S companies such as Pfizer leading the global pharmaceutical industry, in Brazil Aché Laboratorios Farmacéuticos S.A. - a prominent 100-percent Brazilian pharmaceutical corporation – ranks first in the segment, with a revenue of over four billion Brazilian reals in 2021. Focusing mostly on the production and sales of prescription drugs, the company invested more than 81.5 billion reals in research, development, and innovation in 2018.